Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mult Scler Relat Disord ; 85: 105528, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38479046

RESUMO

BACKGROUND: Aquaporin-4 (AQP4) antibody associated neuromyelitis optica (NMOSD) requires long-term immunosuppression. Rituximab is increasingly used worldwide, however the optimal regime is not established. METHODS: We retrospectively examined different rituximab regimens in AQP4-NMOSD. Standard monotherapy (SM; 6 monthly infusions), SM plus oral steroids (SM+S), extended interval dosing (EID; guided by CD19 repopulation) and EID with oral steroids (EID+S) were compared. The primary outcome was time to first clinical relapse. Potential confounders including age, gender, number of previous relapses, and onset phenotype were included. RESULTS: 77 patients were included: 67 females, median onset age 35.6, median DSS at rituximab initiation 5.0. 39 were on SM+S, 20 SM, 6 EID, and 12 EID+S. 25/77 patients relapsed during a median follow-up of 44.0 months. No significant difference in time to first relapse was observed between any rituximab regimen. Pooled analyses to compare regimens that use standard monotherapy (SM and SM+S) against those that use extended interval dosing (EID and EID+S) showed no significant difference. Pooled analysis of regimens using steroids with those not using steroids also showed no significant difference. Adjusted Cox proportional hazard model revealed no significant difference between rituximab regimens or influence of demographic factors. 9 significant adverse events were recorded, 5 in the SM group and 4 in SM+S. CONCLUSIONS: This study provides some basis for further exploring EID as a viable option for long term treatment of AQP4-NMOSD. This may improve patient experience and consolidate use of hospital resources.


Assuntos
Aquaporina 4 , Fatores Imunológicos , Neuromielite Óptica , Recidiva , Rituximab , Humanos , Neuromielite Óptica/tratamento farmacológico , Rituximab/administração & dosagem , Rituximab/farmacologia , Rituximab/efeitos adversos , Feminino , Aquaporina 4/imunologia , Adulto , Masculino , Estudos Retrospectivos , Pessoa de Meia-Idade , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/farmacologia , Autoanticorpos/sangue , Adulto Jovem
2.
Pract Neurol ; 23(6): 512-515, 2023 Nov 23.
Artigo em Inglês | MEDLINE | ID: mdl-37802650

RESUMO

A 21-year-old woman with multiple sclerosis (taking regular fingolimod) developed sudden-onset severe headache with nausea and malaise. Neurological examination was normal and she was afebrile. Blood results showed lymphocytes 0.53 x 109/L and C reactive protein 19 mg/L. CT scan of head and venogram were normal. CSF showed an opening pressure of 33 cm H2O and an incidental light growth of Cryptococcus neoformans, confirmed with positive India Ink stain and a positive cryptococcal antigen (1:100). She was treated for cryptococcal meningoencephalitis with amphotericin and flucytosine. Her presenting symptoms had closely mimicked subarachnoid haemorrhage. This atypical presentation of cryptococcal CNS infection highlights the need for vigilance in immunosuppressed patients.


Assuntos
Meningite Criptocócica , Meningoencefalite , Esclerose Múltipla , Feminino , Humanos , Adulto Jovem , Adulto , Meningite Criptocócica/tratamento farmacológico , Cloridrato de Fingolimode/efeitos adversos , Anfotericina B , Meningoencefalite/tratamento farmacológico
3.
Scand J Gastroenterol ; 51(4): 385-92, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26541790

RESUMO

The diagnosis of inflammatory bowel disease (IBD) remains a challenging task despite significant increase in the understanding of the disease aetiology and pathogenesis. Recent decade has seen a massive interest in the non-invasive diagnostic biomarkers of IBD, consequently a number of studies have explored a variety of potential biomarkers to diagnose the disease and monitor the disease activity. Volatile metabolites are the chemicals, which emanate from biological fluids and can reflect the status of health and disease of an individual. Recent advances in the analytical techniques have enabled the detection and interpretation of the changes in volatile metabolites in breath, urine, faeces and blood of an individual in correlation with various gastrointestinal (GI) disorders including IBD. This can provide a simple, fast and reproducible diagnosis at the point of care. This review focuses on the current and future novel approaches for detecting and the monitoring gut inflammation in IBD by using volatile organic metabolites.


Assuntos
Doenças Inflamatórias Intestinais/diagnóstico , Doenças Inflamatórias Intestinais/metabolismo , Compostos Orgânicos Voláteis/metabolismo , Biomarcadores/análise , Testes Respiratórios , Fezes/química , Humanos , Compostos Orgânicos Voláteis/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...